EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Regimen for accelerated propranolol initial dosing ( RAPID )

Charles Y Huang iD, Marissa J Perman, Albert C Yan

Pediatric Dermatology · 2024

DOI: 10.1111/pde.15623 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Dermatology, 2024. Verfasst von Charles Y Huang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Propranolol. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Infantile hemangiomas are common vascular tumors in children. Propranolol has proven effective in treating infantile hemangiomas and while generally safe, has potential risk for more serious side effects of hypoglycemia, hypotension, bradycardia, bronchospasm, and cardiovascular or respiratory compromise. Current prescribing guidelines recommend initiating propranolol doses at 1 mg/kg/day, with up‐titration to 2 mg/kg/day. This study aims to compare the incidence of adverse events in infants and children treated with propranolol initiated at 1 mg/kg/day versus being initiated directly at 2 mg/kg/day.

Methods

A retrospective cohort study was conducted using medical records of patients receiving propranolol therapy for infantile hemangiomas between October 2018–March 2021 at the Children's Hospital of Philadelphia. Patients were categorized by initial propranolol dosage: 1 or 2 mg/kg/day. The primary outcome measures included parent‐reported adverse events, hypotension (defined by the Pediatric Advanced Life Support criteria), and bradycardia (defined as

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PropranololHumansRetrospective StudiesInfantFemaleMaleHemangiomaChild, PreschoolDose-Response Relationship, DrugBradycardiaDrug Administration ScheduleHypotensionAdrenergic beta-AntagonistsSkin NeoplasmsInfant, Newborn

Stichwörter der Autor:innen

infantile hemangiomapropranolol

Substanzen

PropranololAdrenergic beta-Antagonists

Autor:innen und Institutionen

  • Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Charles Y Huang

Zitieren

APA

Huang, C. Y., Perman, M. J., & Yan, A. C. (2024). Regimen for accelerated propranolol initial dosing ( RAPID ). Pediatric Dermatology. https://doi.org/10.1111/pde.15623

Vancouver

Huang CY, Perman MJ, Yan AC. Regimen for accelerated propranolol initial dosing ( RAPID ). Pediatric Dermatology. 2024. doi:10.1111/pde.15623

BibTeX
@article{Huang2024,
  author = {Huang, Charles Y and Perman, Marissa J and Yan, Albert C},
  title = {Regimen for accelerated propranolol initial dosing ( RAPID )},
  journal = {Pediatric Dermatology},
  year = {2024},
  doi = {10.1111/pde.15623}
}
Kostenlos starten →